For patients with localized prostate cancer, androgen deprivation therapy may be harmful

the ONA take:

According to a new study published in the Journal of OncoTargets and Therapy, researchers from Tulane University in New Orleans, Louisiana, have found that primary androgen deprivation therapy (PADT) was linked with increased all-cause mortality and prostate cancer-specific mortality when compared with radical prostatectomy among men with clinically localized prostate cancer.

For the study, researchers identified 1,624 men diagnosed with clinically localized prostate cancer who underwent PADT and 1,624 men with clinically localized prostate cancer who underwent a radical prostatectomy.

Of the 1,624 patients who received PADT, about 16% died of any cause and 4% died specifically from prostate cancer. of the 1,624 men who opted for radical prostatectomy, about 3% died of any cause and 0.25% died specifically from prostate cancer. The researchers found that the 8-year survival rate among patients who received PADT was approximately 44% and 80% in the radical prostatectomy group.

The findings suggest that PADT was associated with a higher all-cause and prostate cancer-specific mortality compared with radical prostatectomy in patients with clinically localized prostate cancer. Therefore, PADT may not be a good choice as treatment for patients with localized prostate cancer.

For patients with localized prostate cancer, androgen deprivation therapy may be harmful
Primary ADT linked with increased all-cause mortality and prostate cancer-specific mortality.

A widely used treatment for prostate cancer may cause more harm than good for some patients, according to Dr. Oliver Sartor, medical director of the Tulane Cancer Center. For decades, many men diagnosed with prostate cancer were treated with androgen deprivation therapy (ADT), injections that suppressed testosterone production.

Sartor's research has revealed and a new study corroborates this is the wrong approach for selected men with localized disease, as it provides no added survival benefit and may be associated with other serious health issues.

READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs